AMTI - Applied Molecular Transport Inc. Stock Price, Fair Value and News

$0.26

Market Closed

AMTI Stock Valuation Analysis

Valuation

Max Portfolio %

AMTI Price Action

AMTI RSI Chart

AMTI Stock Valuation Analysis

Valuation

Max Portfolio %

AMTI Valuation

AMTI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AMTI Fundamentals

AMTI Earnings

AMTI Profitability

AMTI Investor Care

Revenue & Growth

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

CEO	Mr. Shawn M. Cross
WEBSITE	appliedmt.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	13